BiotechTube

AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes type1

Conditions

Diabetes type1

Trial Timeline

Oct 24, 2018 → Oct 13, 2021

NCT ID
NCT03751007

About AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose

AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose is a phase 1/2 stage product being developed by Precigen for Diabetes type1. The current trial status is completed. This product is registered under clinical trial identifier NCT03751007. Target conditions include Diabetes type1.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03751007Phase 1/2Completed

Competing Products

20 competing products in Diabetes type1

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33
exenatide and sitagliptin + exenatide and placeboEli LillyApproved
85

Other Products from Precigen

Zopapogene imadenovec (Zopa)Approved
80
PRGN-2009 plus Pembrolizumab + Pembrolizumab alonePhase 2
47
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2Phase 1/2
36
INXN-4001Phase 1
28
Fludarabine + Cyclophosphamide + PRGN-3007Phase 1
28